Cara Therapeutics Inc banner

Cara Therapeutics Inc
NASDAQ:CARA

Watchlist Manager
Cara Therapeutics Inc Logo
Cara Therapeutics Inc
NASDAQ:CARA
Watchlist
Price: 18.2486 USD 243.02%
Market Cap: $83.4m

During the last 3 months Cara Therapeutics Inc insiders have not bought any shares, and have not sold any shares.

The last transaction was made on Feb 28, 2025 by Posner Christopher , who sold 2.8k USD worth of CARA shares.

Last Transactions:
Terrillion Scott
$-257
Posner Christopher
$-921.5
Posner Christopher
$-585.3
Posner Christopher
$-29.6
Posner Christopher
$-40.3
Posner Christopher
$-81.8
Goncalves Joana
$-63.1
Terrillion Scott
$-63.1
Terrillion Scott
$-81
Posner Christopher
$-144.2
Goncalves Joana
$-81
Posner Christopher
$-523.6
Posner Christopher
$-75.9
Posner Christopher
$-128.1
Posner Christopher
$-368.4
Terrillion Scott
$-242.2
Goncalves Joana
$-266.8
Menzaghi Frederique Ph.d.
$-291.3
Posner Christopher
$-470.8
Terrillion Scott
$-338.8
Goncalves Joana
$-338.8
Menzaghi Frederique Ph.d.
$-373.2
Terrillion Scott
$-1.7k
Goncalves Joana
$-1.7k
Menzaghi Frederique Ph.d.
$-1.8k
Posner Christopher
$-1.6k
Goncalves Joana
$-642.6
Terrillion Scott
$-114.5
Maynard Ryan D
$-80.6
Goncalves Joana
$-114.5
Posner Christopher
$-1.4k
Goncalves Joana
$-681
View All Transactions

During the last 3 months Cara Therapeutics Inc insiders have not bought any shares, and have not sold any shares.

The last transaction was made on Feb 28, 2025 by Posner Christopher , who sold 2.8k USD worth of CARA shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Cara Therapeutics Inc
Insider Trading Chart

Cara Therapeutics Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Cara Therapeutics Inc
Last Insider Transactions

Global
Insiders Monitor

Cara Therapeutics Inc
Glance View

Market Cap
83.4m USD
Industry
Pharmaceuticals

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The company is headquartered in Stamford, Connecticut and currently employs 84 full-time employees. The company went IPO on 2014-01-31. The firm is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The firm is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates. The firm also initiated a pharmacokinetic safety trial of multiple doses of Oral CR845 in hemodialysis patients to define bioequivalent tablet strengths to inform its ability to develop an oral tablet formulation for moderate-to-severe uremic pruritus. CR701 is a peripherally restricted, mixed-CB1/CB2 receptor agonist that selectively interacts with these cannabinoid receptor subtypes, with no off-target activities.

CARA Intrinsic Value
12.0935 USD
Overvaluation 34%
Intrinsic Value
Price $18.2486

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett